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Background: Recruitment into surgical RCTs can be threatened if new interventions available outside
the trial compete with those being evaluated. Adapting the trial to include the new intervention may
overcome this issue, yet this is not often done in surgery. This paper describes the challenges, rationale
and methods for adapting an RCT to include a new intervention.
Methods: The By-Band study was designed in the UK in 2009–2010 to compare the effectiveness of
laparoscopic adjustable gastric band and Roux-en-Y gastric bypass for severe obesity. It contained a pilot
phase to establish whether recruitment was possible, and the grant proposal specified that an adaptation
to include sleeve gastrectomy would be considered if practice changed and recruitment was successful.
Information on changing obesity surgery practice, updated evidence and expert opinion about trial design
were used to inform the adaptation.
Results: The pilot phase recruited over 13months in 2013–2014 and randomized 80 patients (79
anticipated). During this time, major changes in obesity practice in the UK were observed, with gastric
band reducing from 32⋅6 to 15⋅8 per cent and sleeve gastrectomy increasing from 9⋅0 to 28⋅1 per cent.
The evidence base had not changed markedly. The British Obesity and Metabolic Surgery Society and
study oversight committees supported an adaptation to include sleeve gastrectomy, and a proposal to do
so was approved by the funder.
Conclusion: Adaptation of a two-group surgical RCT can allow evaluation of a third procedure and
maintain relevance of the RCT to practice. It also optimizes the use of existing trial infrastructure to
answer an additional important research question. Registration number: ISRCTN00786323 (http://www
.isrctn.com/).
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Introduction
Large-scale RCTs in surgery can be difficult to design
and conduct. There are challenges with recruitment, inter-
vention complexity and outcome assessment. Recruitment
may be slow because surgeons and associated clinical teams
(such as anaesthetists, nurses, dieticians and psychologists)
are unfamiliar with presenting uncertainty and recruiting
patients, and there is often a lack of clinical trials research
infrastructure in surgical departments1–3. As a result,
extensions to the recruitment period may be required or
the trial may be stopped early before the target sample size
is reached4,5. The additional time taken to deliver surgical
trials has important implications over and above increased
research costs, meaning that the initial research question
can become outdated owing to changing practice. Often,
new interventions are introduced while the trial is recruit-
ing, despite a lack of evidence from RCTs for effective-
ness. This may be due to ‘fashion and popular opinion’,
‘common sense/plausibility’, ‘marketing by industry’ or by
‘influential opinion leaders’. Surgical practice can there-
fore change, and new interventions can be widely imple-
mented, without evaluation and before outcomes from the
trial are available. This contrasts with the introduction of
new medicines, which requires formal evaluation and strict
adherence to governance procedures before licensing for
general use.
The adoption of new but unevaluated surgical interven-
tions outside a trial can threaten the viability of an on-
going trial in a number of ways. Participating surgeons may
want to undertake the new intervention, reducing the pro-
portion of patients offered the trial. In the case of a new
medication, this can be controlled to some extent by a com-
missioning decision that themedication should be available
‘only in research’6. Although this option may be available
for surgical interventions in some countries, surgeons are
rarely willing to apply it voluntarily. Thus, patients can
remain outside a trial and have the new intervention, as
is evidenced by the way in which new surgical interven-
tions are often introduced and adopted7,8. In the absence of
an ‘only in research’ ruling, patients themselves may pre-
fer the new intervention (albeit based on limited evidence
and understanding). It is also possible that centres and sur-
geons may choose not to join the trial because the research
question may appear obsolete, although there is a lack of
high-quality evidence to inform such judgements.
One approach to keeping a trial relevant is to use an
adaptive design. The term is used most often in the con-
text of changing interventions, or respecifying the com-
parator, as evidence emerges about the interventions being
evaluated9. For example, by evaluating short-term out-
comes (or side-effects), a decision can made to drop an
intervention when the accruing data confidently show that
it could never be effective – on grounds of futility. Impor-
tantly, adaptive trial protocols specify criteria for adding or
dropping interventions before the trial begins. Although
there is increasing knowledge and acceptance of the use
of adaptive trial designs for novel pharmaceutical interven-
tions, the principle has been applied less often in trials of
surgery.
Adapting a surgical trial is challenging. It may be difficult
to agree when a new surgical intervention is sufficiently
well developed and standardized for evaluation, and to
establish when surgeons have sufficient experience of it to
contribute to its evaluation in a trial.
The aim of this article is to describe methods that were
used to adapt a surgical RCT to include an additional,
emerging surgical technique. The methods were applied in
what started as the By-Band study of two different bariatric
surgical techniques10, now adapted to the By-Band-Sleeve
study to include an additional evaluation of sleeve gastrec-
tomy.
Methods
The By-Band study was a multicentre pragmatic RCT
undertaken in the UK with the aim to evaluate the effec-
tiveness and cost-effectiveness of two interventions, laparo-
scopic adjustable gastric band and laparoscopic Roux-en-Y
gastric bypass. It was designed in two phases. The first
phase was set up in two centres to examine recruitment.
This internal pilot phase included formal progression crite-
ria/goals (Table 1), whichwere prespecified and approved by
the funder. Formal review of phase 1 was scheduled to take
place after the study had been open for 2 years. The fun-
der agreed that if the criteria/goals were met the trial could
continue into the second phase. Full details of the protocol
are available elsewhere10. The protocol allows all eligible
trial participants to join the study. Those who do not con-
sent to randomization are invited to contribute data on the
operation chosen and participate in follow-up. These data
will be used to understand the generalizabilty of the study
results.
When the study was designed in 2009–2010, gastric band
and bypass accounted for 80 per cent of all bariatric opera-
tions in the National Health Service (NHS)11. A new oper-
ation, sleeve gastrectomy, was starting to be performed,
but accounted for only 8 per cent of operations. Sur-
geons’ experience of sleeve gastrectomy was limited, few
long-term outcome data were available, and there was no
consensus on how the operation should be performed. The
By-Band research team therefore decided that it was not
appropriate to include sleeve gastrectomy as a third group
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Table 1 Details of pre-agreed recruitment and retention goals (‘progression criteria’) in the internal pilot phase of the study, and actual
progress achieved
Pre-agreed goals to be achieved Actual progress achieved
To screen 400 patients 333 patients were screened (83 per cent of that expected in original grant
application)
Sixty per cent of screened patients were eligible 231 patients (69⋅4 per cent) were found to be eligible
To increase recruitment rates from 30 per cent over the first
18 months of recruitment, rising to 50 per cent thereafter*
Recruitment rates were 27 per cent over the first 6 months of recruitment,
rising to 39 per cent thereafter (target 79 randomized, achieved 80)
Less than 5 per cent did not receive allocated treatment 2 of 57 (4 per cent) failed to receive the allocated treatment
Less than 5 per cent lost to follow-up 1 (2 per cent) withdrawn
To reconsider the role of sleeve gastrectomy and whether a
three-group study should be proposed
Sleeve data presented. The proposal to adapt the trial was approved by the
funder
*Recruitment rate is the percentage of eligible patients consenting to join the randomized study.
at that time. This information was presented in the grant
application, with a brief proposal to review with the trial
steering committee the case for adding a sleeve group at
the end of the internal pilot phase. The proposal recog-
nized that, if the trial was adapted, an increase in sample
size would likely be needed.
Criteria for progression from the pilot to the main
trial
The goals used for progression from the phase 1 pilot
to the main trial (phase 2) comprised five recruitment
and protocol adherence-based measures. The study team
also planned to develop a core outcome set during the
pilot (Table 1)12. An intervention to optimize recruitment
was included in the pilot because of well recognized
strong preferences for interventions amongst patients
and surgeons. The Quintet Recruitment Intervention
(QRI) was used13. This has two major components:
understanding recruitment as it happens and then devel-
oping a plan of action to address identified difficulties;
and optimizing informed consent in collaboration with
the RCT chief investigator and the clinical trials unit.
The QRI has been used successfully in several surgical
trials.
Methods for proposing an adaptation to include
sleeve gastrectomy
Four sources of information were reviewed to determine
whether adaptation to include sleeve gastrectomy should
be recommended: data on current surgical practice includ-
ing both NHS and private healthcare provision; published
comparative evidence and ongoing trials; expert surgical
opinion (trial steering and data monitoring and safety com-
mittees, and specialist society); and published data on the
stability of sleeve gastrectomy. The evidence collated was
submitted to the funder with the proposal to adapt the
trial to include a third group, changing the trial identity
to By-Band-Sleeve.
Implementation of the adaptation
A list of practical and logistical steps needed to imple-
ment an adaptation from two to three groups was drawn
up. These steps included considering the implications
for trial participants at different stages of the trial (for
example, invited to take part but not consented, consented
but not randomized, randomized but awaiting surgery, in
follow-up). A strategy for how to proceed was prepared.
Results
Progression from phase 1 to phase 2 of the trial
The grant opened in January 2012 and the formal review
of phase 1 took place in January 2014. The study opened
to recruitment in the first centre in November 2012, and
in the second in February 2013. Between November 2012
and December 2013, 80 patients were recruited and ran-
domized (79 anticipated). The other goals for progression
to the main trial were also met (Table 1). The funder there-
fore agreed that the trial should progress to phase 2 and
expand. Eleven centres are currently participating in the
trial; four phase 2 centres opened before the adaptation to
By-Band-Sleeve, and five opened after the trial had been
adapted.
Adaptation to include sleeve gastrectomy
Changes in current surgical practice
Data from the National Bariatric Surgery Registry were
reviewed to inform the rates of each type of operation11.
Rates of sleeve gastrectomy increased from 9⋅0 to 28⋅1 per
cent during phase 1 (Table 2). Over the same period, the
rates for gastric bypass remained stable and the proportion
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Table 2 Rates of laparoscopic Roux-en-Y gastric bypass, laparoscopic adjustable gastric band and sleeve gastrectomy in the National
Health Service and private sector, 2008–2013
2008–2009 2011 2012 2013
NHS and private practice
Band 2132 (32⋅6) 1316 (25⋅5) 1358 (24⋅8) 891 (15⋅8)
Bypass 3817 (58⋅4) 3030 (58⋅8) 2894 (52⋅9) 3176 (56⋅2)
Sleeve 588 (9⋅0) 809 (15⋅7) 1218 (22⋅3) 1587 (28⋅1)
Total 6537 5155 5470 5654
NHS only (HES data)
Band n.a. 637 (16⋅9) 736 (18⋅2) 506 (11⋅0)
Bypass n.a. 2540 (67⋅6) 2394 (59⋅1) 2816 (61⋅1)
Sleeve n.a. 583 (15⋅5) 922 (22⋅8) 1290 (28⋅0)
Total n.a. 3760 4052 4612
Private practice only*
Band n.a. 679 (48⋅7) 622 (43⋅9) 385 (36⋅9)
Bypass n.a. 490 (35⋅1) 500 (35⋅3) 360 (34⋅5)
Sleeve n.a. 226 (16⋅2) 296 (20⋅9) 297 (28⋅5)
Total n.a. 1395 1418 1042
Values in parentheses are percentages. *Data likely to be under reported. NHS, National Health Service; HES, Hospital Episodes Statistics; n.a., not
available.
of operations using gastric band surgery declined from
32⋅6 to 15⋅8 per cent overall. Analysis of data by NHS
and private provision showed that, in the NHS, gastric
band surgery accounted for just 11⋅0 per cent of bariatric
procedures in 2013, but in the private health sectors band
surgery remained the most common operation (Table 2).
This pattern was mirrored elsewhere in the world14.
Published comparative evidence and ongoing trials
The Cochrane systematic review of bariatric surgery that
had informed the original By-Band grant application was
updated and published in 201415. The authors concluded
that there remained a lack of high-quality evidence for
the different types of bariatric surgery. The trials reviewed
were primarily small single-centre studies performed out-
side the UK. They were at risk of bias and focused
predominantly on short-term outcomes up to 1 year. Inter-
rogation of clinical trials registries identified three ongoing
trials evaluating sleeve gastrectomy16–18. These were also
small, non-UK, single-centre studies. The evidence from
completed trials, and the evidence that would be gener-
ated from ongoing trials, was judged to be inadequate to
draw any definitive conclusion about the effectiveness of
the three types of operation.
Expert opinion
The proposal to adapt the trial was discussed at a spe-
cial session of the British Obesity and Metabolic Surgery
Society annual meeting in January 2014. Those present
supported it, and additional centres were recruited. The
independent trial steering and data monitoring committees
supported the adaptation.
447 Sleeve 447 Bypass 447 Band
Eligible for By-Band-Sleeve study (60% expected)
All patients referred for bariatric surgery
Randomized
Estimated 85% followed to primary outcome,
n = 1140 in primary analyses at 3 years
Total participants n = 1341
Fig. 1 By-Band-Sleeve trial design
Intervention stability
At the time when the trial was first designed there was
little consensus regarding sleeve gastrectomy itself and how
it should be performed and followed up. By the time of
the review, best practice guidelines had been published
and the fourth international consensus summit for sleeve
gastrectomy had taken place19,20. Meetings confirmed that
the procedure was safe, and agreed standards for its conduct
were documented.
Research question
The proposal for adaptation to a three-group trial was
reviewed and accepted by the funder. The original research
question, (1) below, was expanded in the three-group trial
to answer three questions based on co-primary outcomes:
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Table 3 Practical and logistical considerations for optimizing adaptation of a two-group to three-group surgical trial
Consideration Potential problems Suggestions to optimize adaptation
Study logo and
acronym
If the acronym and study logo are specific to the two
groups (e.g. By-Band), they will need to be changed
(e.g. to By-Band-Sleeve). This may: (1) create changes
to study and website materials that would not
otherwise be necessary, and (2) jeopardize the
branding of the study
At the outset, select an acronym and study logo that
could encompass a future adaptation
Data collection
forms
New and updated case report forms needed. This may: (1)
take a lot of time and involve significant changes to the
forms, and (2) lead to major changes to the database
Design case report forms in logical sections. For
example, separate information and adverse event data
that are common for all surgical procedures from that
which is specific to one procedure. Organizing the data
collection in this way can help minimize the database
changes needed
Allocation of
procedures
If equal allocation of participants to groups is applied after
the adaptation, this will result in unbalanced numbers
of participants in each group at the end of the trial
Close working with senior statisticians is recommended.
If the allocation ratio is adjusted, simulation of future
recruitment at each centre is needed to ensure that the
allocation remains concealed and cannot be predicted.
Rigorous testing of all changes needs to be performed
Alternatively, the allocation ratio can be adjusted so that
the numbers per group are approximately equal at the
end of the trial when the target sample size is reached.
In modifying the allocation ratio, it is necessary: (1) to
consider the projected recruitment rate and numbers
recruited already in each centre before the adaptation,
and (2) to assess the impact the change of ratio will
have on future recruitment
This work would need to be included in the overall cost of
the adaptation
Transition pathway
for participants
at different
stages of trial
Information provision for participants during trial adaption
needs consideration, especially for those part way
through recruitment. Each (potential) participant will be
at one of five stages; they may have: (1) been sent
information about the two-group study but not yet had
a consultation, (2) discussed the two-group study but
not yet consented to randomization, (3) been
consented to the two-group study but not yet
randomized, (4) been randomized and awaiting surgery,
or (5) undergone surgery and be in follow-up
It is recommended that the trial team discusses the
transition with individual centres. It is particularly
important to agree the process for patients at stages (1)
and (3). In By-Band-Sleeve, these patients had had a
consultation in which two procedures were discussed
and it was not feasible for them to have a further
consultation. Randomization for these patients was
therefore handled centrally by the trials unit to prevent
them being allocated to the new procedure
1. Does gastric bypass lead to better quality of life and
at least as good weight loss as gastric band (original
question)?
2. Does sleeve gastrectomy lead to better quality of life
and at least as good weight loss as gastric band (new
question)?
3. Does sleeve gastrectomy lead to better quality of life
and at least as good weight loss as gastric bypass (new
question)?
When calculating the sample size for the adapted design,
the same assumptions as for the original calculations were
used10. Because the number of hypotheses was increased
threefold, the significance levels were adjusted from 5 to 2
per cent for the two-sided statistical tests of superiority and
from 2⋅5 to 1 per cent for the one-sided statistical tests of
non-inferiority. Under these assumptions, the revised total
sample size for a trial with equal allocation across the three
treatment groups was 1341 (447 per group) (Fig. 1).
The formal proposal for the adaptation was submitted at
the same time as the request to progress from the pilot to
the main trial. Approval and additional funding to support
the adaptation was granted in October 2014.
Implementation of the adaptation
Practical and logistical changes necessary to adapt a sur-
gical trial are outlined in Table 3. All patient-facing study
documents had to be revised and submitted as a major
amendment to the research ethics committee for approval.
Data collection forms needed to be extended to capture the
additional surgical procedure. The randomization scheme
had to be revised to allow future participants to be allocated
to one of the three surgical procedures. The allocation ratio
was modified to ensure there would be approximately equal
numbers of participants per group at the end of the trial, to
provide the same power for all comparisons. Adjustment to
the allocation ratio was determined by simulation to ensure
balance was achieved, while at the same time ensuring
that allocation would be unpredictable to prevent alloca-
tion bias. The allocation ratio chosen was specific to each
study centre, depending on the numbers recruited before
the adaptation and the projected recruitment rate going
© 2017 The Authors. BJS published by John Wiley & Sons Ltd www.bjs.co.uk BJS 2017; 104: 1207–1214
on behalf of BJS Society Ltd.
1212 C. A. Rogers, B. C. Reeves, J. Byrne, J. L. Donovan, G. Mazza, S. Paramasivan et al.
200
400
600
N
o.
 r
ec
ru
ite
d
800
0
Jan 2013 Jan 2014 Jan 2015
Recruitment month
Jan 2016 Jan 2017
Actual recruitment
Target recruitment
Fig. 2 Recruitment into the By-Band-Sleeve study at January
2017
forward. Each centre needed guidance on: when to col-
lect data using the By-Band data collection forms and when
to collect data using the revised By-Band-Sleeve forms;
when to start using the revised patient information leaflets;
and when the randomization system and database would
be switched over and how to manage participants who had
given consent but had not been randomized at the time of
the switch (Table 3).
The adapted By-Band-Sleeve study opened to recruit-
ment in August 2015, 13months after approval from the
funder to proceed with the adaptation. The transition went
smoothly and the study is recruiting steadily to all three
procedures (Fig. 2). In February 2017, the 50 per cent
recruitment milestone was reached (671 patients random-
ized into the trial). All study centres continue to be sup-
ported with the QRI13.
Discussion
This paper describes adaptation of a two-group RCT in
bariatric surgery to a three-group trial. The adaptation
was proposed because of changing clinical practice, namely
the increasing uptake of a new procedure in the absence
of high-quality evidence of its clinical effectiveness com-
pared with the procedures already being evaluated. The
trial team was aware of the interest in the new procedure
when designing the By-Band study, and specified the possi-
bility of an adaptation in the original grant proposal. This
stated that if recruitment in the internal pilot phase proved
possible the trial team would consider whether adapting
to a three-group trial was relevant (and present a new
proposal to the funder). This approach to designing and
conductingRCTs in surgery is recommended, although not
often used. It ensures the continued relevance of the trial to
surgeons, allows efficient use of trial resources, and enables
a procedure that has stabilized and is being widely used
to undergo comparative rigorous evaluation.
Adapting a surgical RCT has proved challenging, with
practical and scientific implications and complexities.
The majority of experience has been gained in pharma-
ceutical studies where the pressure to adapt a trial arises
from the emergence of competing ‘like-me’ drugs9, and
with pressure to evaluate multiple new drugs. In phar-
maceutical trials short-term or surrogate endpoints are
typically used to inform adaptation decisions. In trials
with longer-term endpoints (the primary endpoint of
By-Band-Sleeve is at 3 years), it is not sensible to adapt
the trial based on short-term outcomes, especially if no
appropriate short-term surrogate measure exists. How-
ever, as shown here, there is an opportunity to introduce
additional group(s) to evaluate new intervention(s). The
By-Band-Sleeve study also includes a ‘non-randomized’
cohort of eligible patients who consent to data collection
and follow-up but not to randomization. Analysis of this
cohort will provide important insights into how the trial
has been integrated into each clinical practice at the study
centres.
One challenge to overcome when a study changes from
two to three groups is to ensure that trial processes are not
disrupted during the transition and that patients continue
to be recruited and followed up in accordance with the
protocol. For example, some patients were consented to
a two-group trial but, by the time they were randomized,
the trial had switched to three groups. It was not feasible
to have a further consultation to discuss the trial again, so
the randomization for these patients was handled centrally
by the trials unit to avoid them being allocated to the new
procedure.
Another decision that needs to be made is whether the
allocation ratio should be chosen to create approximately
equally sized groups at the end of the trial, or whether
the ratio should be 1 : 1 : 1 going forward, accepting that
the sample size for the two original study groups will be
larger than that for the new group. In the By-Band-Sleeve
adaptation, the allocation ratio at each centre was adjusted
to achieve approximately equal allocation overall. Although
the revised allocation ratio should provide comparable
power for all group comparisons, it is not without ‘risks’.
A balanced allocation may not be achieved if the trial
© 2017 The Authors. BJS published by John Wiley & Sons Ltd www.bjs.co.uk BJS 2017; 104: 1207–1214
on behalf of BJS Society Ltd.
Adaptation of a randomized trial to include a new intervention 1213
stops early for any reason, or if the recruitment rates differ
significantly from those predicted.
The primary reason for adapting a trial to include a new
procedure is to keep it up-to-date and relevant to clinical
practice. It is, however, important to adapt a trial and
include a new procedure only when surgeons are com-
fortable to discuss clinical equipoise with patients. These
issues are challenging, because surgeons may naturally
believe that the new procedure has advantages and they
will find it more interesting/exciting to do a new proce-
dure rather than a standard technique. In these situations,
surgeons may state that a randomized evaluation is not
possible because it is ‘too late’ and they do not have clinical
equipoise. This view is represented in Buxton’s law which
says: ‘it is always too early for rigorous evaluation until,
unfortunately, it’s suddenly too late’21. Despite this estab-
lished mantra, there have been several recent examples of
successful surgical trials in which surgeons have been sup-
ported to provide balanced information to inform patient
decision-making and ensure successful recruitment22,23.
Because of the success of these other trials, this support
was included in By-Band and By-Band-Sleeve. The QRI
uses qualitative methods to understand how surgeons
communicate information to patients. Consultations
are audiorecorded and analysed, and meetings are held
with surgeons to provide training in how to optimize
informed consent. Although this approach to supporting
trial recruitment represents progress for randomized trials,
there is a need to use these methods to optimize infor-
mation provision in other settings when surgeons talk to
patients, such as during early-phase studies and with the
introduction of novel techniques.
This article describes an example of adaption from a two-
to a three-group surgical trial to include an increasingly
prevalent intervention and allow its evaluation in a prag-
matic study. The inclusion of an internal pilot and a formal
review of success in recruiting to the two-group design pro-
vided a convenient interval in which to consider whether a
third group should be added. The justification was based
primarily on external sources of information, in contrast
to trial adaptation based on accruing evidence within the
trial. This approach is recommended for RCTs in surgery
to optimize the efficiency of the trial team infrastructure,
allow surgeons to undertake an additional intervention, and
maintain the relevance of the research question.
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Editor’s comments
This paper reviews the process whereby the BY-BAND trial design was modified to move from a two-arm to a
three-arm design. The problem posed for evaluation of surgery by randomized clinical trials when sudden swings
of enthusiasm for new procedures occur in the profession are well set out, and the argument for an adaptive trial as
a response is well made. The detailed mechanics of how the trial was altered while under way may not be of interest
to all readers of BJS, but it may be useful to investigators considering a similar problem. This study may be a good
example to improve surgical research, and promotes high quality clinical studies to bring evidence-based medicine in
the surgical community.
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